Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood (2023) 142 (Supplement 1): 299.

https://doi.org/10.1182/blood-2023-173615

Published: 2023

Journal Articles

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Blood (2023) 142 (Supplement 1): 979.

https://doi.org/10.1182/blood-2023-188788

Published: 2023

Journal Articles

Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Eva Hoster, Marie-Helene Delfau, Elizabeth A. Macintyre, Linmiao Jiang, Stephan Stilgenbauer, Ursula Vehling-Kaiser, Gilles Salles, Catherine Thieblemont, Hervé Tilly, Lothar Kanz, Pierre Feugier, Kai Huebel, Christian Schmidt, Vincent Ribrag, Hanneke Kluin-Nelemans, Martin Dreyling, Christiane Pott

Blood (2022) 140 (Supplement 1): 1304–1306.

https://doi.org/10.1182/blood-2022-159932

Published: 2022

Journal Articles

Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial

Blood (2021) 138 (Supplement 1): 379.

https://doi.org/10.1182/blood-2021-149600

Published: 2021

Journal Articles

P16, c-Myc, SOX11, P53, ki67 and CD71Protein Expression in Aggressive Morphological Variants of Mantle Cell Lymphomas Compared to Classical Morphological Mantle Cell Lymphomas in Multiple Clinical Trials

Barbara Burroni, Anne Moreau, MD, Mathieu Baldacini, MD, Antoine Martin, MD PhD, Steven Le Gouill, Vincent Ribrag, Rémy Gressin, MD, Chantal Brochet, Martin H. Dreyling, MD PhD, Samuel Griolet, Yannick Le Bris, PharmD, Morgane Cheminant, MD, Hanneke Kluin-Nelemans, MD, Olivier Hermine, MD PhD, Luc Mathieu Fornecker, MD PhD, Alexandra Traverse-Glehen, MD PhD, Danielle Canioni, MD

Blood (2019) 134 (Supplement_1): 2820.

https://doi.org/10.1182/blood-2019-129790

Published: 2019

Journal Articles

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)

Martin Dreyling, MD, Eva Hoster, PhD, Michael Unterhalt, PhD, Andreas Rosenwald, MD, Hanneke Kluin-Nelemans, MD, Olivier Hermine, MD PhD, Wolfram Klapper

Blood (2019) 134 (Supplement_1): 3996.

https://doi.org/10.1182/blood-2019-130068

Published: 2019

Journal Articles

KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

Blood (2018) 132 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2018-99-115895

Published: 2018

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network

Sietse M. Aukema, Eva Hoster, Andreas Rosenwald, Danielle Canoni, Marie-Hélène Delfau-Larue, Grzegorz Rymkiewicz, Christoph Thorns, Sylvia Hartmann, Hanneke Kluin-Nelemans, Olivier Hermine, Martin Dreyling, Wolfram Klapper

Blood (2018) 131 (4): 417–420.

https://doi.org/10.1182/blood-2017-07-797019

Published: 2018

Includes: Supplemental data

Journal Articles

Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)

Massimiliano Bonifacio, MD, Patrizia Bonadonna, MD, Hanneke Oude Elberink, MD, Björn van Anrooij, MD, Aleksandra Górska, MD, Magdalena Lange, MD, Emir Hadzijusufovic, DVM, Luigi Scaffidi, Ilaria Tanasi, MD, Cecelia Perkins, Virginia Valeria Ferretti, Anja Illerhaus, PhD, Thilo Jakob, MD, Roberta Parente, MD, Mohamad Jawhar, MD, Francesca Caroppo, MD, Alexander Zink, MD, Alex Kilbertus, MD, Akif Selim Yavuz, MD, Michael Doubek, MD PhD, Hans Hagglund, MD PhD, Jens P. Panse, MD, Vito Sabato, MD PhD, Elisabeth Aberer, MD, Nadja Jaekel, MD, Peter Vandenberghe, MD PhD, David Fuchs, MD, Knut Brockow, MD, Anna Belloni Fortina, MD, Andreas Reiter, MD, Massimo Triggiani, MD, Khalid Shoumariyeh, MD, Karin Hartmann, MD, Chiara Elena, Olivier Hermine, MD PhD, Jason Gotlib, MD, Marek Niedoszytko, MD, Hanneke Kluin-Nelemans, MD PhD, Wolfgang R. Sperr, MD, Peter Valent, MD, Roberta Zanotti, MD

Blood (2017) 130 (Supplement 1): 4200.

https://doi.org/10.1182/blood.V130.Suppl_1.4200.4200

Published: 2017

Journal Articles

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Blood (2017) 130 (Supplement 1): 2916.

https://doi.org/10.1182/blood.V130.Suppl_1.2916.2916

Published: 2017

Journal Articles

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

Blood (2017) 130 (Supplement 1): 153.

https://doi.org/10.1182/blood.V130.Suppl_1.153.153

Published: 2017

Journal Articles

Selection and Efficacy of Cytoreductive Agents in Patients with Mastocytosis Included in the Registry of the European Competence Network on Mastocytosis (ECNM)

Blood (2017) 130 (Supplement 1): 1650.

https://doi.org/10.1182/blood.V130.Suppl_1.1650.1650

Published: 2017

Journal Articles

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis

Blood (2013) 121 (13): 2393–2401.

https://doi.org/10.1182/blood-2012-09-458521

Published: 2013

Includes: Supplemental data

Journal Articles

First Report of the HOVON 45: A Phase II Study with Rituximab, High Dose Ara-C and Autologous Stem Cell Transplantation in the Primary Treatment of Mantle Cell Lymphoma.

Mars B. Van’t Veer, MD, PhD, Annelise Notenboom, PhD, Marius McKenzie, MD,PhD, Hanneke Kluin-Nelemans, MD,PhD, Rien van Oers, MD,PhD, Jose Zijlstra, MD, Daphne de Jong, MD,PhD, Pieter Sonneveld, MD,PhD, Anton Hagenbeek, MD,PhD

Blood (2006) 108 (11): 2734.

https://doi.org/10.1182/blood.V108.11.2734.2734

Published: 2006

Journal Articles

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Frank Morschhausser, Martin Wolf, John Seymour, Herve Tilly, Michael Pfreundschuh, Hanneke Kluin-Nelemans, John Raemaekers, Mars B. van’t Veer, Noel Milpied, Guillaume Cartron, Antonio Pezzutto, Andrew Spencer, Christelle Darstein, Donald Thornton, Martin Dreyling, Felix Reyes

Blood (2006) 108 (11): 2450.

https://doi.org/10.1182/blood.V108.11.2450.2450

Published: 2006

Journal Articles

Disruption of the Hexb/Enc-1 Antisense Gene and Identification of Elevated Enc-1 Expression in Patients with Hairy Cell Leukemia.

Mikael Lerner, Marianne Hammarsund, PhD, Olle Sangfelt, PhD, Chaoyong Zhu, PhD, Mats Merup, MD, PhD, Monika Jansson, Goesta Gahrton, MD, PhD, Hanneke Kluin-Nelemans, MD, PhD, Stefan Einhorn, MD, PhD, Dan Grander, MD, PhD, Martin Corcoran, PhD

Blood (2004) 104 (11): 1538.

https://doi.org/10.1182/blood.V104.11.1538.1538

Published: 2004

NARROW

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial

P16, c-Myc, SOX11, P53, ki67 and CD71Protein Expression in Aggressive Morphological Variants of Mantle Cell Lymphomas Compared to Classical Morphological Mantle Cell Lymphomas in Multiple Clinical Trials

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)

KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network

Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

Selection and Efficacy of Cytoreductive Agents in Patients with Mastocytosis Included in the Registry of the European Competence Network on Mastocytosis (ECNM)

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis

First Report of the HOVON 45: A Phase II Study with Rituximab, High Dose Ara-C and Autologous Stem Cell Transplantation in the Primary Treatment of Mantle Cell Lymphoma.

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Disruption of the Hexb/Enc-1 Antisense Gene and Identification of Elevated Enc-1 Expression in Patients with Hairy Cell Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only